Loading...
OTCM
TRUMY
Market cap20bUSD
Jul 09, Last price  
13.73USD
1D
-1.44%
1Q
2.01%
Jan 2017
-25.78%
Name

Terumo Corp

Chart & Performance

D1W1MN
OTCM:TRUMY chart
P/E
24.19
P/S
2.90
EPS
92.14
Div Yield, %
Shrs. gr., 5y
-0.51%
Rev. gr., 5y
13.02%
Revenues
1.13t
+9.24%
276,439,000,000306,381,000,000302,746,000,000316,009,000,000328,214,000,000386,686,000,000402,294,000,000467,359,000,000489,506,000,000525,026,000,000514,164,000,000587,775,000,000599,481,000,000628,897,000,000613,842,000,000703,303,000,000820,209,000,000921,863,000,0001,036,171,000,0001,131,877,000,000
Net income
135.91b
+16.19%
37,232,000,00043,382,000,00036,878,000,00040,721,000,00032,338,000,00024,167,000,00047,014,000,00034,096,000,00038,470,000,00050,676,000,00054,225,000,00091,295,000,00079,470,000,00085,211,000,00077,268,000,00088,813,000,00089,325,000,000106,374,000,000116,978,000,000135,914,000,000
CFO
230.85b
+9.51%
43,123,000,00069,683,000,00031,615,000,00067,352,000,00046,828,000,00056,200,000,00050,270,000,00096,259,000,00073,110,000,00080,303,000,00080,862,000,000114,562,000,00093,571,000,000117,479,000,000121,485,000,000141,467,000,000117,536,000,000146,330,000,000210,802,000,000230,852,000,000
Dividend
Sep 28, 20230.6002 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
IPO date
Jun 21, 1982
Employees
30,207
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT